Punit Dhillon

Company: Skye Bioscience

Job title: Chief Executive Officer

Seminars:

Peripheral CB1 Inhibition: A Novel Approach to Sustainable Weight Loss and Improved Metabolic Health 9:30 am

Uncover the unique approach to obesity treatment with nimacimab, a first-in-class peripheral CB1 inhibitor, by modulating energy expenditure and fat metabolism, while preserving muscle mass Discover the potential of nimacimab to offer a safer, more tolerable weight loss option with a favorable gastrointestinal profile and minimal neuropsychiatric side effects, addressing common concerns associated with current…Read more

day: Conference Day Two